# MIBG With Dinutuximab +/- Vorinostat

> **NCT03332667** · PHASE1 · COMPLETED · sponsor: **New Approaches to Neuroblastoma Therapy Consortium** · enrollment: 45 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **RADIATION:** 131I-MIBG
- **DRUG:** Dinutuximab
- **DRUG:** Vorinostat
- **DRUG:** Sargramostim
- **DRUG:** Potassium Iodide

## Key facts

- **NCT ID:** NCT03332667
- **Lead sponsor:** New Approaches to Neuroblastoma Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-12
- **Primary completion:** 2024-02-23
- **Final completion:** 2024-02-23
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03332667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03332667, "MIBG With Dinutuximab +/- Vorinostat". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03332667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*